Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Positive Data For Threshold-Suspend Feature Of Medtronic Insulin Pump

This article was originally published in The Gray Sheet

Executive Summary

Medtronic says the ability to automatically suspend insulin delivery when glucose levels drop to a preset threshold is an important technological milestone en route to a fully automated artificial pancreas.

Advertisement

Related Content

Medtronic Sees Long-Awaited Approval Of MiniMed 530G As A Big Step In Artificial Pancreas “Journey”
News Briefs: Medtronic’s First-Gen Artificial Pancreas Approved; CMS Removes Bariatric Surgery Requirements
FDA Audit Slows Down Medtronic Launch Plans For Low-Glucose-Suspend Diabetes System
Medtronic Aims To Double Its Presence In Emerging Markets By 2015-2016
Research In Brief

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

MT032191

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel